Have You Or Has Someone In Your Family Been Diagnosed With Lung Cancer?
Did you know that 1 in 4 people diagnosed with lung cancer have the KRAS-variant, an inherited gene mutation that provides powerful, life-saving information about how an individual will respond to specific cancer treatments?
If you or a family member has had lung cancer, you are eligible to join a study to explore the relationship between genes and cancer treatment. If you would like to join a study, please complete the eligibility survey.
What we know about the KRAS-variant:
- Found in 6-10% of the population
- Predicts sensitivity and resistance to several standard-of-care cancer treatments/therapies
- Associated primarily with post-menopausal cancer in women, enabling the opportunity for cancer prevention through informed decision making about oophorectomy (ovarian removal) at menopause
- Explains the genetic cause of cancer for over 50% of Hereditary Breast and Ovarian Cancer (HBOC) families with no other known genetic markers
- Cancer risk may be influenced by estrogen loss
TAKE THE ELIGIBILITY SURVEY
We encourage you to see if you are eligible to join a MiraKind study to help us discover meaningful ways to better treat patients with genetic mutations. If you would like to join a study, please click the button below. You will be able to choose to get your KRAS-variant results at a discounted cost ($195) through the study. If you would prefer to directly order KRAS-variant testing at cost ($295) without joining a study, please follow this link.
MiraKind’s pipeline of planned and ongoing research studies are designed to protect the health of individuals with the KRAS-variant and to help answer the most pressing questions about cancer. Research questions include:
- What are the best cancer management strategies for KRAS-variant cancer patients
- What environmental factors, hormone exposures, medicines, or other lifestyle factors can influence cancer risk for individuals with the KRAS-variant?
- How can cancer survivors who are positive for the KRAS-variant protect themselves from secondary cancers?
- How can we prevent cancers associated with the KRAS-variant for family members who are positive but have never been diagnosed with cancer?